- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03117452
Evaluation of a Visual Remediation Intervention for Schizophrenia
March 28, 2018 updated by: Judy L. Thompson, Ph.D., Rutgers, The State University of New Jersey
Schizophrenia is a severe psychiatric condition that is associated with significant distress and disability.
In addition to cognitive difficulties in domains such as attention, memory, and problem-solving, individuals with schizophrenia can experience visual-processing abnormalities, including impairments in visual acuity, low-contrast stimulus detection, and perceptual organization (i.e., perceiving visual information in an organized "perceptual whole").
These visual impairments are clinically significant, with research indicating that specific visual-processing alterations are significantly related to poorer performance on higher-level cognitive tasks, impaired facial emotion recognition, impaired reading ability, and worse functional outcomes.
Despite such findings, very few studies have evaluated the therapeutic potential of interventions that are specifically designed to improve visual processing ("visual remediation") for individuals with schizophrenia.
Thus the aim of this study is to evaluate the efficacy of a computerized visual perceptual training program that targets low- and mid-level visual processes to improve visual, cognitive, and emotion-recognition functions in outpatients with schizophrenia through a small randomized controlled trial.
The investigators will recruit up to 40 individuals with schizophrenia or schizoaffective disorder who are receiving treatment in Rutgers University Behavioral Health Care (UBHC) Partial Hospital Program; half will be randomized to receive the computerized visual training, which will be delivered in small groups over a period of 12-14 weeks.
The specific aims of this study are to collect preliminary data on: 1) the feasibility of participant recruitment and retention, and tolerability of the treatment components of the study; and 2) the efficacy of computerized visual training (VT) to improve low- and mid-level visual processes, and higher-level cognitive and social-cognitive performance.
Based on preliminary data, the investigators hypothesize that the target number of participants will be successfully recruited and engaged in the VT intervention (n=16) and control condition (n=16), and that the participants who receive VT will demonstrate greater improvements on measures of low- and mid-level visual, higher-level cognitive, and social-cognitive functions compared to those who receive standard partial-hospital care without VT.
The results of this initial trial will be used to inform the design and application for funding of a larger-scale investigation of visual remediation for individuals with schizophrenia.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Judy L. Thompson, Ph.D.
- Phone Number: 732-235-9297
- Email: judy.thompson@rutgers.edu
Study Contact Backup
- Name: Steven M. Silverstein, Ph.D.
- Phone Number: 732-235-5149
- Email: steven.silverstein@rutgers.edu
Study Locations
-
-
New Jersey
-
Piscataway, New Jersey, United States, 08854
- Recruiting
- Rutgers University Behavioral Health Care (UBHC)
-
Contact:
- Judy L. Thompson, Ph.D.
- Phone Number: 732-235-9297
- Email: judy.thompson@rutgers.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Between the ages of 18-60.
- Meets DSM-5 criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder.
- Currently attends the Rutgers UBHC Partial Hospital Program and plans to continue attending for at least the next 16 weeks.
- If the participant is treated with antipsychotic medication, he/she is on stable treatment with this medication (i.e. no change in medication type, or substantial change in dose, for at least 4 weeks prior to participating in the study and no anticipated change for the next 16 weeks).
- Has capacity to provide informed consent.
- Is fluent in English.
- Has a minimum binocular visual acuity of 20/100, as assessed at baseline using a standard eye chart, with the participant's typical vision correction (e.g., with glasses if the participant typically wears glasses).
Exclusion Criteria:
- Has met DSM-5 criteria for a substance-use disorder within the last 12 months (with the exception of tobacco use disorder, which will be permitted).
- Has a verbal IQ score of < 70 per the Wechsler Test of Adult Reading (WTAR).
- Current or recent history of a medical condition that significantly affects the structure or function of the brain or eye (e.g., ocular or retinal disease, thyroid disease, untreated hypertension, uncontrolled diabetes).
- Current or past neurological or neurodevelopmental disorder such as seizure disorder, cerebral palsy, intellectual disability, or pervasive developmental disorder.
- Has a "lazy eye" or history of severe eye injury.
- Has received electroconvulsive therapy within the last 8 weeks.
- Has a history of head injury with loss of consciousness lasting more than 10 minutes or with neurobehavioral consequences of the injury (e.g., need for follow-up treatment, cognitive or behavioral changes following the injury, etc.).
- Any current use (last month) of non-prescribed amphetamines, opiates, cocaine, sedative-hypnotics, and/or cannabis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: visual training condition
Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes.
Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
|
The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes.
Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
|
No Intervention: control condition
Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
contrast sensitivity
Time Frame: approximately 14 weeks (baseline and post-treatment)
|
A measure of low-contrast stimulus detection; contrast sensitivity thresholds at varying spatial frequencies will be examined.
|
approximately 14 weeks (baseline and post-treatment)
|
contour integration
Time Frame: approximately 14 weeks (baseline and post-treatment)
|
A measure of visual perceptual organization; total number correct, adjusted for guessing, will be examined.
|
approximately 14 weeks (baseline and post-treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Judy L. Thompson, Ph.D., Rutgers University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 23, 2017
Primary Completion (Anticipated)
February 28, 2019
Study Completion (Anticipated)
February 28, 2019
Study Registration Dates
First Submitted
April 12, 2017
First Submitted That Met QC Criteria
April 17, 2017
First Posted (Actual)
April 18, 2017
Study Record Updates
Last Update Posted (Actual)
March 30, 2018
Last Update Submitted That Met QC Criteria
March 28, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro20160000350
- PC 51-16 (Other Grant/Funding Number: New Jersey Health Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Visual Training
-
HES-SO Valais-WallisUniversity of Applied Sciences of Western SwitzerlandUnknownHemispatial NeglectSwitzerland
-
National Cheng-Kung University HospitalNot yet recruitingDevelopmental Delay | Preterm Children
-
University of MilanCompleted
-
National Taiwan University HospitalNot yet recruitingConvergence InsufficiencyTaiwan
-
University of WaterlooKing Saud UniversityCompleted
-
Wrocław University of Science and TechnologyRecruiting
-
University of SalfordUniversity of Nottingham; University of Birmingham; Stroke Research Network; University...Completed
-
State University of New York College of OptometryState University of New York College of OptometryRecruitingQuality of Life | Visual Impairment | Functional Visual Loss | Low Vision BlindnessUnited States
-
University of MinnesotaNational Institute of Mental Health (NIMH)RecruitingPsychotic Disorders | Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Schizoaffective Disorder | Psychosis | Schizo Affective Disorder | Schizophreniform Disorders | Psychoses, Affective | Psychotic Mood Disorders | Psychosis Nos/OtherUnited States
-
University of Alabama at BirminghamUniversity of California, RiversideRecruitingMacular Degeneration | Central Visual ImpairmentUnited States